This company listing is no longer active
BNO Stock Overview
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bionomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.011 |
| 52 Week High | AU$0.073 |
| 52 Week Low | AU$0.01 |
| Beta | 2.13 |
| 11 Month Change | -8.33% |
| 3 Month Change | -50.00% |
| 1 Year Change | -78.85% |
| 33 Year Change | -91.85% |
| 5 Year Change | -97.90% |
| Change since IPO | -97.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNO | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 10.0% | -0.3% | 0.9% |
| 1Y | -78.8% | 11.0% | 18.4% |
Return vs Industry: BNO underperformed the Australian Biotechs industry which returned -9.1% over the past year.
Return vs Market: BNO underperformed the Australian Market which returned 1.8% over the past year.
Price Volatility
| BNO volatility | |
|---|---|
| BNO Average Weekly Movement | 19.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: BNO's share price has been volatile over the past 3 months.
Volatility Over Time: BNO's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited Fundamentals Summary
| BNO fundamental statistics | |
|---|---|
| Market cap | AU$14.69m |
| Earnings (TTM) | -AU$24.91m |
| Revenue (TTM) | AU$6.02m |
2.4x
P/S Ratio-0.6x
P/E RatioIs BNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNO income statement (TTM) | |
|---|---|
| Revenue | AU$6.02m |
| Cost of Revenue | AU$19.80m |
| Gross Profit | -AU$13.79m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$24.91m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -229.04% |
| Net Profit Margin | -413.94% |
| Debt/Equity Ratio | 0% |
How did BNO perform over the long term?
See historical performance and comparison